In a significant ruling impacting India's pharmaceutical regulatory framework, the Supreme Court has upheld a Himachal Pradesh High Court judgment limiting the independent enforcement powers of inspectors of the Central Drugs Standard Control Organisation (CDSCO).
The dispute arose from the interpretation of Chapter IV of the Drugs and Cosmetics Act, 1940, which governs the manufacture, sale, and distribution of drugs and cosmetics in India. The Union Government had challenged the High Court's decision, arguing that CDSCO inspectors possessed the authority to independently inspect pharmaceutical establishments, collect drug samples, and initiate prosecutions for violations under the Act.
Dismissing the government's challenge, the Supreme Court allowed the High Court ruling to stand. As a result, CDSCO inspectors cannot independently exercise such enforcement powers unless expressly authorized within the statutory framework. The judgment reinforces the principle that regulatory authorities must operate strictly within powers conferred by legislation.
The ruling is expected to have substantial implications for regulatory oversight within the pharmaceutical sector. Industry stakeholders anticipate that enforcement actions may require greater coordination with state drug regulatory authorities, which traditionally exercise powers under the Drugs and Cosmetics Act.
Legal experts note that the decision highlights the importance of statutory interpretation in administrative and regulatory law. It also underscores judicial scrutiny of executive action where enforcement powers are exercised beyond the scope expressly granted by Parliament.
The judgment may prompt policymakers and regulators to examine whether legislative amendments are necessary to clarify the role and powers of CDSCO inspectors in ensuring drug safety and compliance across the country.